APA (7th ed.) Citation

Tharmaseelan, H., Gillessen, S., Bühnen, I., Kaul, H., Kobe, C., Schrenk, K. G., . . . von Tresckow, B. (2025). 828 | TRIAL IN PROGRESS: PEMBROLIZUMAB IN COMBINATION WITH SALVAGE CHEMOTHERAPY FOR FIRST‐RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (PEMBRO‐CORE). Hematological oncology, 43, 1. https://doi.org/10.1002/hon.70096_828

Chicago Style (17th ed.) Citation

Tharmaseelan, H., et al. "828 | TRIAL IN PROGRESS: PEMBROLIZUMAB IN COMBINATION WITH SALVAGE CHEMOTHERAPY FOR FIRST‐RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (PEMBRO‐CORE)." Hematological Oncology 43 (2025): 1. https://doi.org/10.1002/hon.70096_828.

MLA (9th ed.) Citation

Tharmaseelan, H., et al. "828 | TRIAL IN PROGRESS: PEMBROLIZUMAB IN COMBINATION WITH SALVAGE CHEMOTHERAPY FOR FIRST‐RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (PEMBRO‐CORE)." Hematological Oncology, vol. 43, 2025, p. 1, https://doi.org/10.1002/hon.70096_828.